U.S. markets open in 9 hours 28 minutes
  • S&P Futures

    4,349.75
    +6.50 (+0.15%)
     
  • Dow Futures

    33,851.00
    +53.00 (+0.16%)
     
  • Nasdaq Futures

    15,031.25
    +7.25 (+0.05%)
     
  • Russell 2000 Futures

    2,185.30
    +4.40 (+0.20%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,778.10
    -0.10 (-0.01%)
     
  • Silver

    22.78
    +0.17 (+0.75%)
     
  • EUR/USD

    1.1723
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.3240
    +0.0150 (+1.15%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3650
    -0.0015 (-0.11%)
     
  • USD/JPY

    109.4790
    +0.2590 (+0.24%)
     
  • BTC-USD

    42,064.26
    -636.68 (-1.49%)
     
  • CMC Crypto 200

    1,041.06
    -22.79 (-2.14%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,667.12
    -172.59 (-0.58%)
     

3 Things About Cassava Sciences That Smart Investors Know

·5 min read
3 Things About Cassava Sciences That Smart Investors Know
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Like other biotechs without any revenue, its value proposition to shareholders is contingent on the success of its clinical trials. The company's drug, simufilam, recently completed its phase 2 clinical trials, and the company plans to start phase 3 before the end of 2021. On July 29, Cassava reported a packet of data showing that simufilam improved cognition, slowed the progression of Alzheimer's disease, and elicited positive changes in a smattering of biomarkers.